Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sunkyu Kim

Showing results (41-50 of 65) with videos related to

Pageof 7
Sort By:
Cancer Discovery|July 12, 2013
An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide)Manav Korpal, Joshua M Korn, Xueliang Gao, et al.
Journal of the American Medical Informatics Association : JAMIA|August 21, 2023
Evaluation of crowdsourced mortality prediction models as a framework for assessing artificial intelligence in medicineTimothy Bergquist, Thomas Schaffter, Yao Yan, et al.
Oncoimmunology|December 29, 2025
A dual diacylglycerol kinase (DGK) alpha/zeta inhibitor augments the activity of human tumor infiltrating lymphocytes in <i>in vivo</i> and <i>ex vivo</i> modelsPhurin Areesawangkit, Karen Pei-Yi Fong, Emma Niemeyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 13, 2016
Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in NeuroblastomaLori S Hart, JulieAnn Rader, Pichai Raman, et al.
Journal of Medicinal Chemistry|April 17, 2026
Discovery of INCB191358: A Potent and Selective DGKα/ζ Dual InhibitorBo Wei, Xiaolei Li, Jacob J Lacharity, et al.
Cancer Cell|July 9, 2014
CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitorsSadhna R Vora, Dejan Juric, Nayoon Kim, et al.
Journal of Medicinal Chemistry|November 3, 2010
4-(Pyrazol-4-yl)-pyrimidines as selective inhibitors of cyclin-dependent kinase 4/6Young Shin Cho, Maria Borland, Christopher Brain, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2013
Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastomaJulieann Rader, Mike R Russell, Lori S Hart, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2016
Dual <i>ALK</i> and <i>CDK4/6</i> Inhibition Demonstrates Synergy against NeuroblastomaAndrew C Wood, Kateryna Krytska, Hannah T Ryles, et al.
Journal of Medicinal Chemistry|March 16, 2017
Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERα+ Breast CancerHeather E Burks, Tinya Abrams, Christina A Kirby, et al.
Pageof 7

Showing results (41-50 of 65) with videos related to

Sort By:
Pageof 7
Cancer Discovery|July 12, 2013
An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide)Manav Korpal, Joshua M Korn, Xueliang Gao, et al.
Journal of the American Medical Informatics Association : JAMIA|August 21, 2023
Evaluation of crowdsourced mortality prediction models as a framework for assessing artificial intelligence in medicineTimothy Bergquist, Thomas Schaffter, Yao Yan, et al.
Oncoimmunology|December 29, 2025
A dual diacylglycerol kinase (DGK) alpha/zeta inhibitor augments the activity of human tumor infiltrating lymphocytes in <i>in vivo</i> and <i>ex vivo</i> modelsPhurin Areesawangkit, Karen Pei-Yi Fong, Emma Niemeyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 13, 2016
Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in NeuroblastomaLori S Hart, JulieAnn Rader, Pichai Raman, et al.
Journal of Medicinal Chemistry|April 17, 2026
Discovery of INCB191358: A Potent and Selective DGKα/ζ Dual InhibitorBo Wei, Xiaolei Li, Jacob J Lacharity, et al.
Cancer Cell|July 9, 2014
CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitorsSadhna R Vora, Dejan Juric, Nayoon Kim, et al.
Journal of Medicinal Chemistry|November 3, 2010
4-(Pyrazol-4-yl)-pyrimidines as selective inhibitors of cyclin-dependent kinase 4/6Young Shin Cho, Maria Borland, Christopher Brain, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2013
Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastomaJulieann Rader, Mike R Russell, Lori S Hart, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2016
Dual <i>ALK</i> and <i>CDK4/6</i> Inhibition Demonstrates Synergy against NeuroblastomaAndrew C Wood, Kateryna Krytska, Hannah T Ryles, et al.
Journal of Medicinal Chemistry|March 16, 2017
Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERα+ Breast CancerHeather E Burks, Tinya Abrams, Christina A Kirby, et al.
Pageof 7